This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Deal: Onyx Tanks on Report Amgen's Interest Cooling

Stocks in this article: AMGN ONXX

NEW YORK ( TheStreet) -- Shares of Onyx Pharmaceuticals (ONXX) tanked 7.2% to $115.34 on concerns that Amgen's (AMGN) interest in the biopharmaceutical company might have waned.

Last week, Onyx said multiple parties remain interested in acquiring the cancer drug developer, but the public nature of the deal talks have raised doubts about the outcome.

Onyx said June 30 that it received interest from Amgen at $120 per share, which the company rejected. In early August, media reports suggested Amgen was offering $130 per share. Now Bloomberg has reported that Amgen has agreed on the $130 price but conditioned upon reviewing data on Onyx's Kyprolis proteasome inhibitor, which is in accelerated approval with the Food and Drug Administration. Phase 3 trial results for the multiple myeloma treatment are expected by early 2014.

Amgen said the reports that it was seeking information on Kyprolis did not originate from Amgen.

Onyx declined to comment except to reiterate that multiple parties remain interested in a potential deal.

The major concern seems to be that the Onyx auction is not as robust as initially expected, with hopes of a price topping $150 per share for the company.

The public nature of the negotiation suggests that Onyx does not have as much active interest as the company expected.

The odd element to the reports is the notion that Amgen is looking for additional data on Kyprolis application that is not yet available. Amgen did not have the data when it pitched its $120 offer in late June or when the bidder apparently raised to $130 earlier this month.

Interim data on Kyprolis is not important enough to derail a deal with Amgen, a sell-side analyst said. An interim look is neither crucial nor definitive, and the request for unavailable data is unreasonable on the surface, the analyst said. It feels more like Amgen, if the story is accurate, does not think it faces competition in the auction, the analyst said. But the availability of an interim update on Kyprolis is not worth screwing up a deal over $10 per share, the analyst said.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs